At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Post-Mkt 08-05 17:12:44 EDT
1.80
-0.10
-5.26%
盘后1.72
-0.08-4.44%
16:55 EDT
High1.95Low1.73Vol35.32K
Open1.95D1 Closing1.90Amplitude11.60%
Mkt Cap1.91MTradable Cap1.91MTotal Shares1.06M
T/O65.67KT/O Rate3.34%Tradable Shares1.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers
Reuters  ·  08-04 21:16
Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers
Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells
THOMSON REUTERS  ·  08-04 21:15
Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells
Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons
Reuters  ·  08-01
Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
TIPRANKS  ·  07-29
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
THOMSON REUTERS  ·  07-29
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months
THOMSON REUTERS  ·  07-29
Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months
Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026
THOMSON REUTERS  ·  07-29
Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026
Silexion Therapeutics Shareholders Raise Authorized Share Capital Via Memorandum Amendment
Reuters  ·  07-22
Silexion Therapeutics Shareholders Raise Authorized Share Capital Via Memorandum Amendment
Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)
TIPRANKS  ·  06-25
Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)
Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split
THOMSON REUTERS  ·  06-24
Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split
Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial
Reuters  ·  06-23
Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial
Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany
THOMSON REUTERS  ·  06-23
Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany
Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany
THOMSON REUTERS  ·  06-23
Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany
Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer
Reuters  ·  06-22
Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer
Silexion Therapeutics management to attend BIO International Convention 2026
Reuters  ·  06-17
Silexion Therapeutics management to attend BIO International Convention 2026
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
TIPRANKS  ·  06-13
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
Silexion Therapeutics executes 1-for-10 reverse share split
Reuters  ·  05-29
Silexion Therapeutics executes 1-for-10 reverse share split
Silexion Therapeutics Corp trading halted, news pending
TIPRANKS  ·  05-29
Silexion Therapeutics Corp trading halted, news pending
Silexion Therapeutics announces 1-for-10 reverse share split
Reuters  ·  05-26
Silexion Therapeutics announces 1-for-10 reverse share split
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
THOMSON REUTERS  ·  05-26
Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--